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Abstract
Background: To assess the blood pressure and lipid-lowering efficacy and tolerability of ‘polypills’ used in cardiovascular
disease prevention trials.
Methodology/Principal Findings: Systematic review and meta-analysis. Search strategy: The Cochrane Central Register of
Controlled Trials, Medline, and PubMed databases were searched for eligible trials. Study inclusion criteria: Randomised
controlled trials of at least six weeks duration, which compared a ‘polypill’ (that included at least one anti-hypertensive and
one lipid-lowering medication) with a placebo (or one active component). Outcome measures: Change from baseline in
systolic and diastolic blood pressures, and total and LDL-cholesterol; discontinuation of study medication and reported
adverse effects. Of 44 potentially eligible studies, six trials (including 2,218 patients without previous cardiovascular disease)
fulfilled the inclusion criteria. Compared with placebo, ‘polypills’ reduced systolic blood pressure by 29.2 mmHg (95%
confidence interval (CI): 213.4, 25.0) diastolic blood pressure by 25.0 mmHg (95%CI: 27.4, 22.6), total cholesterol by
21.22 mmol/L (95%CI: 21.60, 20.84) and LDL-cholesterol by 21.02 mmol/L (95%CI: 21.37, 20.67). However, those taking
a ‘polypill’ (vs. placebo or component) were more likely to discontinue medication (20% vs 14%) (Odds ratio: 1.5 (95% CI: 1.2,
1.9)). There was no significant difference in reported adverse effects amongst those on a ‘polypill’ (36% vs. 28%) (OR: 1.3
(95%CI: 0.7, 2.5)). There was high statistical heterogeneity in comparisons for blood pressure and lipid-lowering but use of
random-effects and quality-effects models produced very similar results.
Conclusions/Significance: Compared with placebo, the ‘polypills’ reduced blood pressure and lipids. Tolerability was lower
amongst those on ‘polypills’ than those on placebo or one component, but differences were moderate. Effectiveness trials
are needed to help clarify the status of ‘polypills’ in primary care and prevention strategies.
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Introduction
Cardiovascular disease is the leading cause of death worldwide.
[1] On the basis of a substantial body of evidence, cardiovascular
guidelines have recommended that those with a past history of
cardiovascular disease [2] or who otherwise have a high risk of
disease [3] follow lifestyle interventions and receive blood pressure
lowering [4] and lipid-lowering medications, [5,6] and where
benefit outweighs risk, aspirin therapy. [7,8] This combination of
therapies substantially reduces risk of future cardiovascular events.
[9,10,11] Despite guidelines, high proportions of those at high
cardiovascular risk are not prescribed these preventive medica-
tions, particularly in low income countries. [12,13,14] Besides
relatively low rates of prescribing of recommended medications,
long-term adherence to medications is also low, which further
compromises the preventive potential of these medications. A 2003
World Health Organisation (WHO) report estimated that less than
50% of those prescribed long-term medications for chronic
conditions take their medications regularly. [15] Each additional
cardiovascular medication prescribed tends to be associated with
lower adherence. [16] Adherence also reduces sharply in the first
year after commencing medication, although adherence is better if
medications are initiated together. [15,17] The WHO report
recommends that interventions to improve adherence should be
developed and could improve health outcomes to a greater extent
than developing new medications. [15] Using fixed dose combi-
nations, or ‘polypills’, that combine generic versions of different
classes of preventive medications for high risk individuals is one
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such strategy, as it may simplify the medication regime for both
prescriber and patient and reduce cost for health funder and
patient. [18,19].
In 2001, a WHO and Wellcome Trust meeting of experts
concluded that a fixed-dose combination pill containing aspirin,
statin and two blood pressure (BP) lowering agents may improve
adherence to treatment as well as substantially reduce the cost of
the drugs, particularly for low and middle income countries. [20]
In 2003, Wald and Law claimed that ischemic heart disease could
be reduced by 88% and strokes by 80% if all those over 55 years of
age were given a ‘polypill’ containing three low-dose blood
pressure lowering medications, a statin, low dose aspirin and folic
acid. [11] This controversial approach of ‘medicalising’ the
population has been followed by more targeted approaches of
‘polypills’ recommended for high risk individuals only, where
effectiveness and cost-effectiveness are likely to be most favourable.
[21] An important aspect of the ‘polypills’ is their affordability,
particularly for low-income countries where cardiovascular
mortality is increasing. [22].
Evidence for fixed-dose combination (FDC) medications has
been promising, as shown by a meta-analysis of antihypertensive
FDCs. [23] In 2002, the WHO recommended that bioavailability,
pharmacokinetics, effects on risk factors and side effects of
‘polypill’ formulations should be assessed by short-term efficacy
trials, followed by community-based effectiveness trials and cost-
effectiveness evaluations comparing ‘polypills’ to standard prac-
tice. [20] It has taken more than 10 years to progress these aims.
Several efficacy trials of ‘polypills’ including at least one
antihypertensive and one lipid-lowering medication have been
conducted. Some are placebo-controlled while others have active
component comparators. This systematic review and meta-
analysis aimed to assess the efficacy and tolerability of the
‘polypill’ approach by examining the effects on blood pressure,
lipid profiles and discontinuation and side effects of medication.
Methods
Ethics Statement
This was a meta-analysis of published summary data and
therefore did not require ethics approval.
Definition of a ‘Polypill’
For the purposes of this review, a ‘polypill’ has been defined as a
medication formulation containing at least one blood pressure
lowering medication and one lipid-lowering medication (with or
without an anti-platelet agent such as aspirin).
Selection of Studies
This meta-analysis included randomised controlled trials of
cardiovascular ‘polypills’ that were published in English. Trials of
at least six weeks duration were eligible to allow reasonable
estimation of clinical effect and likely discontinuation of medica-
tion. Trials must have assessed at least one primary outcome of this
review, which included systolic and diastolic blood pressure, serum
total and LDL-cholesterol and a measure of tolerability, either
discontinuation of medication or proportion reporting side effects.
The comparator could be placebo or component medications that
allowed a placebo comparison for at least one primary outcome.
The Cochrane Central Register of Controlled Trials, Medline,
and PubMed databases were searched for eligible trials using the
terms in Table S1. The strategy was guided by the Cochrane
Systematic Review Handbook. [24] Reference lists were also
searched. A second researcher undertook an independent litera-
ture search of Medline, PubMed and Embase (Table S2).
Study Procedures
Data were extracted on design, intervention, duration of follow-
up, sample size (intervention and control) and follow-up rate.
Study population demographic, cardiovascular risk and co-
morbidity characteristics were also recorded. Data extraction
was undertaken separately by two researchers. Study quality was
assessed using the Jadad criteria where a score out of five is given
for description and appropriateness of randomisation and blind-
ing, and for description of withdrawals and drop-outs. [25] The
Cochrane criteria for risk of bias were also used to assess study
quality. [24] Change in outcome measures in each group over the
trial was recorded. Authors were contacted where data were
missing. The number and proportion of study participants who
discontinued the study medication during the trial and the
proportion of participants with side effects were compared
between intervention and control groups.
Statistical Analysis
The weighted mean difference in continuous outcomes was
calculated using Cochrane RevMan 5.1 software [24] and checked
by a separate researcher using STATA (v12, StataCorp LP).
Means and standard deviations of change of the primary outcome
measures were used where reported. Where standard deviations
could not be obtained from the published data or from contacting
the authors, standard deviations from baseline were used. [26]
Where there was no placebo control, comparators not containing
an anti-hypertensive for blood pressure analyses or not containing
a lipid-lowering medication for lipid analyses were used. Odds
ratios and 95% confidence intervals were calculated for dichot-
omous variables. Heterogeneity was investigated using Tau2 and I2
statistics. Where substantial statistical heterogeneity was found,
random-effects models were used and compared with quality-
effects models. [27] Publication bias was investigated using Begg’s
rank correlation and Egger’s regression methods in STATA v12,
and funnel plots in RevMan. [28,29,30] Sensitivity analyses were
carried out on the basis of duration of follow-up, as it was
hypothesized that effect size may reduce if adherence decreased
over time.
Results
Of the 44 studies identified by the literature search, six fulfilled
the inclusion criteria and were included in the meta-analysis
(Figure 1 and Table S1). A search undertaken independently by a
second researcher did not identify any additional eligible studies
(Figure S1). The characteristics and quality of the eligible studies
are included in Table 1.
Characteristics of Studies
The intervention of all trials was a fixed dose combination that
contained either one, two or three antihypertensives (including a
calcium channel blocker [31,32], a thiazide and ACE inhibitor
[33,34], a thiazide, ACE inhibitor and beta-blocker [35], or a
thiazide, angiotensin receptor blocker and a calcium channel
blocker [36]) plus one lipid lowering medication (including
atorvastatin (20 mg) [31,32,34] or simvastatin (20 mg [33,35] or
40 mg [36])). Three ‘polypills’ also included aspirin (75 mg or
100 mg). [33,34,35] The comparison was either a true placebo
[32,33,34] or one cardiovascular component (aspirin [35],
simvastatin [35] or amlodipine [31]). All trials were double-blind.
Five were parallel designs and one was a cross-over design. [36]
One parallel trial included nine arms of varying numbers of fixed
dose components but with no placebo arm. [35] For this trial only
the ‘polycap’ arm and the arms not containing an antihypertensive
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(‘aspirin arm’ and ‘statin arm’) for blood pressure comparisons and
one arm not containing a lipid-lowering agent (‘aspirin arm’) for
lipid comparisons were used. [35] Five studies were of 6–12 weeks
and one trial of 12 months duration. [34] Two other randomised
controlled trials of ‘polypills’ were identified but excluded. One
study compared low-dose with high-dose polycap components but
did not include a placebo arm or reduced number of components
that allowed a placebo comparison of blood pressure or serum
lipid concentrations. [37] The other study was an open label trial
comparing a ‘polypill’ with usual care. [38].
Participant Characteristics
Table 1 summarises the study and participant characteristics. A
total of 2,218 patients were included in the meta-analysis
comparisons. This was made up of 1,116 in a ‘polypill’ group
and 1,102 in a comparison group. No participants had previous
cardiovascular disease but most had at least one cardiovascular
risk factor. Despite this, there were some differences between study
populations. Two trials excluded those with diabetes. [31,32]
Mean baseline systolic blood pressure varied from 125 mmHg
[34] to 147 mmHg [32] in the intervention groups across trials
and the proportion of women participants varied from 19% [33]
to 53%. [31] All trials except two [35,36] allowed concomitant
blood-pressure lowering medication, although levels of use were
low.
Effect on Blood Pressure
Results from five trials, where control arms did not contain
antihypertensive medication, were combined to assess effects of
‘polypills’ on blood pressure lowering (Figure 2). Compared with
placebo, the ‘polypills’ reduced systolic blood pressure by
29.2 mmHg (95% confidence interval (CI): 213.4, 25.0) and
diastolic blood pressure by 25.0 mmHg (95%CI: 27.4, 22.6).
However, there was evidence of significant heterogeneity of trials
(I2 87% and 83%, respectively). A sensitivity analysis including the
four shorter trials of 6 to 12 weeks duration and excluding the
longer trial of 12 months [34], found systolic blood pressure
reduced by 210.8 mmHg (95%CI: 215.2, 26.3), and diastolic
blood pressure by 26.0 mmHg (95%CI: 28.1, 24.0).
Effect on Lipid Profiles
Results from all trials, where the control did not contain lipid-
lowering medication, were combined to assess effects on serum
lipids (Figure 3). Compared with placebo, the ‘polypills’ reduced
Figure 1. Polypills Meta-analysis ‘PRISMA’ Flow Diagram.
doi:10.1371/journal.pone.0052145.g001
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Figure 2. Forest Plots of Polypills versus Control for Change in Systolic and Diastolic Blood Pressure.
doi:10.1371/journal.pone.0052145.g002
Figure 3. Forest Plots of Polypills versus Control for Change in Total Cholesterol and LDL-cholesterol.
doi:10.1371/journal.pone.0052145.g003
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total cholesterol by 21.22 mmol/L (95%CI: 21.60, 20.84) and
LDL-cholesterol by 21.02 mmol/L (95%CI: 21.37, 20.67).
There was high statistical heterogeneity (I2 = 96%). If the 12
month trial was excluded [34], total cholesterol reduced by
21.33 mmol/L (95%CI: 21.72, 20.95) and LDL-cholesterol by
21.13 mmol/L (95%CI: 21.47, 20.79).
Discontinuation of Study Medication and Side Effects
Those taking ‘polypills’ were more likely to discontinue
medication compared with placebo or one component (20% vs
14%) (OR: 1.5 (95%CI: 1.2, 1.9); Figure 4). There was lower
heterogeneity (I2 = 21%) than for the estimates of effects on blood
pressure or lipids. When only comparisons with placebo were
included, [32,33,34] the odds ratio was 1.7 (95%CI: 1.3, 2.3) (24%
vs 16%). Amongst the four trials that reported overall side effects
[31,32,33,36], the difference between ‘polypills’ and comparison
arms in the proportion experiencing side effects (36% vs 28%) was
not statistically significant (OR: 1.3 (95%CI: 0.7, 2.5; I2 = 73%)
(Figure 4). The difference approached significance when only
placebo-controlled trials were compared (45% vs 33%) (OR: 1.7
(95%CI: 0.97, 2.9)).
Study Quality and Potential Bias
Due to the high levels of heterogeneity, quality-effects models
were also conducted and compared with the results from random-
effects models, using MetaXL in Excel. [27] Very similar effect
estimates were obtained (Figure S2). Overall, included trials were
of high quality (Jadad score 4/5 to 5/5), (Table 1). However, there
were differences in baseline systolic blood pressure between
intervention and control groups in the trials of the Pill
Collaborative Group and Malekzadeh et al. (4.0 and 5.5 mmHg,
respectively). [33,34] The latter trial had imbalances in several
baseline characteristics suggesting inadequacy of randomisation.
[34] It also had moderately high rates of attrition from both groups
but more in the intervention group (31% vs 22%), representing
another potential source of bias. Risk of bias in this trial was
therefore ‘‘uncertain’’ according to Cochrane criteria (Table S3).
[24] There was no evidence of publication bias in any of the
analyses (as evaluated by Begg’s and Egger’s tests and graphical
representation using funnel plots (Figure S3)). The PRISMA
checklist can be found for this meta-analysis in Table S4.
Discussion
Summary of Findings
Compared with placebo, the ‘polypills’ reduced systolic blood
pressure by 29.2 mmHg, diastolic blood pressure by
25.0 mmHg, total cholesterol by 21.22 mmol/L and LDL-
cholesterol by 21.02 mmol/L. Those taking a ‘polypill’ were
more likely to discontinue study medication than those taking one
component or placebo, although reported adverse effects were not
significantly different.
Strengths and Limitations
There was significant clinical and statistical heterogeneity
amongst the trials. It may be argued that these studies should
not have been combined in a meta-analysis because they
contained interventions and controls with different components,
and duration of follow-up varied from 6 weeks to 12 months.
However, the meta-analysis assesses the use of cardiovascular
‘polypills’ in a variety of settings and populations, typical of real
Figure 4. Forest Plots of Polypills versus Control for Change in Discontinuation of Study Medication and Side Effects.
doi:10.1371/journal.pone.0052145.g004
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life, where at least one antihypertensive and one lipid-lowering
medication have been combined in a fixed dose combination.
Therefore, heterogeneity would be expected. Random-effects and
quality-effects models found very similar effect sizes. [27] There
are also limitations with using summary level data rather than
individual-level data in a meta-analysis.
Compared with the Literature and Implications for Future
Practice
This meta-analysis reviewed the current evidence for efficacy
and tolerability of cardiovascular ‘polypills’. The ‘polypills’
reduced risk factors compared with placebo; although less than
has been estimated previously. [11] Wald et al estimated that a
cardiovascular ‘polypill’ could reduce LDL cholesterol by
1.8 mmol/L and blood pressure by 20/11 mmHg. Actual
reductions in risk factors depend on baseline risk factor levels
and the number and doses of medications contained within the
polypills. Wald’s estimated reduction in LDL cholesterol used a
baseline of 4.8 mmol/L. [5] A 2003 meta-analysis of statin trials
provides expected reductions in LDL based on statin and dose [5],
from which expected reductions in LDL can be estimated for each
of the trials in this meta-analysis taking into account baseline LDL
level (Table 2). The ‘polypills’ in the trials included within this
meta-analysis contained between one and three anti-hypertensives
with doses of a quarter to twice the standard dose equivalent for
each of these components (Table 2). The observed reductions in
systolic blood pressure and LDL-cholesterol for the ‘polypills’ were
comparable to that expected for two of the trials (Neutel and
Wald). Although the observed reduction in systolic blood pressure
was comparable to that expected in the PILL collaborative trial,
the observed reduction in LDL-cholesterol was only 64% of that
expected. The observed reduction in LDL cholesterol in the
Grimm trial was 89% of that expected. The observed reduction in
systolic blood pressure and LDL-cholesterol were much less than
expected in the Malekzadeh and TIPS trials. This discrepancy
could be explained by the greater loss to follow up in these trials,
which would dilute treatment effect when ‘intention to treat’
analyses are undertaken, a lower adherence rate than reported,
concomitant treatment in the control groups or methodological
issues. However, it may also be closer to the real change in risk
factors likely if used in practice. The trial that found the greatest
reductions in blood pressure and lipids was the trial that had few
participants drop-out, good adherence, and no concomitant blood
pressure and lipid-lowering medication. [36] Almost all the
participants had been taking the component medications prior
to the trial, so presumably would be those most likely to tolerate
and adhere to a combination ‘polypill’. [36] For this type of
patient, we can expect predicted results. The real test will be in
comparing ‘polypills’ to current care.
A short 12-week effectiveness trial comparing a ‘polypill’ with
current care has been completed, but showed no difference
between groups in systolic blood pressure or total cholesterol. [38]
Several longer trials comparing a ‘polypill’ with current care are
well underway or soon to be published. [39,40,41,42,43] The
doses and number of components used will obviously influence
both effectiveness and tolerability. A recent trial showed that
doubling the doses of five ‘polypill’ components resulted in further
significant reductions in systolic blood pressure (2.8 mmHg),
diastolic blood pressure (1.7 mmHg), total cholesterol
(0.19 mmol/L) and LDL-cholesterol (0.17 mmol/L). [37].
Even if the effectiveness of the ‘polypill’ strategy is found only to
be equivalent to current care, cost is likely to be reduced, making
preventive therapies more affordable, particularly for low-income
countries. [22] A large part of the burden of chronic disease,
particularly cardiovascular disease, is now borne by low-income
countries. In 2005, it was estimated that 35 million people would
die from non-communicable chronic diseases around the world.
[22] Cardiovascular disease was found to be the leading single
cause of death and accounted for 20% of the total disability-
adjusted years lost amongst people over 30 years of age globally.
Furthermore, 80% of the burden of chronic disease occurs in
people under the age of 70 years. [22] Rates of preventive therapy
are lower in low- and middle-income countries than in high-
income countries. [44] Patented medications have made many of
the cardiovascular preventive medications prohibitively expensive
for these countries, severely limiting access to medications,
increasing levels of poverty [45] and causing impoverishment in
households struggling to afford medication. [46] The use of
affordable ‘polypills’ could help address this issue.
A recent review of the cost-effectiveness of interventions for
primary prevention of cardiovascular disease found that one of the
‘best value for money’ interventions was a combination of low cost
blood pressure lowering medications and a statin, aimed at those
at increased CVD risk. [47] Modelled cost-effectiveness analyses of
a ‘polypill’ have also been promising in middle and higher income
countries. [48,49] However, the actual clinical and economic
potential of a polypill strategy will require the results of
effectiveness trials that compare ‘polypills’ with current care and
subsequent cost-utility analyses.
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